Splendris International Limited, an affiliate of Shenzhen Salubris Pharmaceuticals Co Ltd., a multi-national leader in the development and commercialization of cardiovascular products in China and beyond, recently announced a strategic investment and in-licensing agreement with Swiss cardiovascular pioneer M.A. MedAlliance S.A.

Under the terms of the agreement, Salubris will make a $20 million equity investment in MedAlliance and will commit an additional $10 million in developmental milestones in exchange for exclusive rights to develop and commercialize MedAlliance’s lead investigational product Selution, a potential best-in-class sirolimus micro-reservoir drug-coated balloon (DCB), for peripheral and cardiovascular applications in the Chinese market. MedAlliance will also be eligible for royalty payments on sales.

MedAlliance’s DCB technology is a next-generation approach for patients with peripheral artery disease (PAD), coronary artery disease (CAD) and arteriovenous fistulas (AVF). With unique micro-reservoirs, the technology efficiently delivers sirolimus to the target lesion, where it provides controlled and sustained release. MedAlliance’s technology will further enable surgeons’ desire to move away from metal scaffolds and durable polymers that remain within the patient in PAD by providing a safer and more effective alternative to paclitaxel-coated balloons.